Piramal expands its high potency API capability25 Jun 2019
Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.
CDMO Piramal Pharma Solutions (PPS) has opened a new wing at its Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs). The total investment required to upgrade the site was approximately $10 million, which includes a new QC/analytical lab and two kilo-labs, as well as a doubling of the office space, which was needed to support the dramatic growth at the Riverview site.
To date, the Riverview site has had the containment capability and engineering controls to safely handle HPAPIs with OELs down to 1 mcg/m3, at scales ranging from grams to approximately 250 kilos. The new wing, which consists of two kilo-labs and a QC/analytical lab, brings more to the table. It has been designed with the required engineering controls and containment solutions to handle HPAPIs with OELs <1 mcg/m3 and as low as approximately 20 ng/m3. Materials will primarily be produced in this new wing at kilo-lab scales; lots of <5 kilos can be produced in this new state-of-the-art facility.
Vivek Sharma, CEO, Piramal Pharma Solutions said: “We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs. It’s another example of how we remain committed to partnering with our customers to serve the patient community and reduce the burden of disease.”
Historically, the site operated as one shift, 5 days a week. Today, the site operates 12 hours a day, 7 days a week, and is headed towards being a full 24/7 site. The Riverview site expansion also provides significant benefits to the local economy, including the addition of new high-tech jobs. The local staff has increased from 80 to 127 people, with a projected total of approximately 150 employees in the near future. This includes high-tech staffing of PhD and BS degreed scientists, plus manufacturing operators and other skilled workers.
Vince Ammoscato, Vice President and Riverview Site Head, added: “This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market. We are equipped to offer ADC customers a seamless end-to-end solution since we can develop the HPAPI payloads and linkers here in Riverview, send them to our site in Scotland for the antibody conjugation, then back to our Lexington, Kentucky site for sterile fill and finish.”
The ability to offer a fully integrated solution for the ADC market – from proof-of-concept studies to conjugation development, clinical and commercial ADC GMP batch manufacturing and fill/finish – represents a significant strategic advantage for Piramal Pharma Solutions.
According to Mr Ammoscato, more expansions are forthcoming. There is additional real estate available on the site for added capacity and new capability enhancements that will be designed to match the market needs of the pharmaceutical industry.
One-stop-platform for plant-based nutraceuticals
2 Oct 2019
In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.Read more
Industry on the brink of a new age of smart pharma manufacturing
27 Sep 2019
Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.Read more
Huge boom in Korean Pharma reported at CPhI Korea
20 Sep 2019
Event sees new Memorandum of Understanding signed by PROLMED and KPTA.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Take part in pharma’s largest reputation survey
6 Sep 2019
Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.Read more
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019
29 Aug 2019
Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019Read more
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator
16 Aug 2019
Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.Read more
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East
5 Aug 2019
Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.Read more
Drive for generics sees Korea increasingly attractive to international pharma
31 Jul 2019
Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.Read more
Huge CPhI & P-MEC China a direct result of surging manufacturing
22 Jul 2019
Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation